The story of copyright's flagship drug presents a complex case for investors in the medicinal sector. While initially a phenomenal success, generating vast sums, the intellectual property lapse and the subsequent arrival of generic versions have drastically affected earnings. This presents questions about the future sustainability of analogous m… Read More